Exploring Investigational Therapies in Low-risk MDS

Several investigational agents are expanding treatment options for patients with Myelodysplastic Syndromes (MDS) by targeting specific cytopenias and disease pathways. Thrombopoietin receptor agonists like eltrombopag are being studied to enhance platelet counts in patients with thrombocytopenia, potentially lowering bleeding risk. Other novel therapies, such as elritercept, are under investigation focus on modulating the bone marrow microenvironment, targeting splicing mutations, or altering disease progression. Collectively, these agents represent a shift toward personalized, mechanism-based treatment strategies designed to improve hematologic outcomes and quality of life in MDS.